journal article·2020-03-14Open access

Development of Scaffolds with Adjusted Stiffness for Mimicking Disease-Related Alterations of Liver Rigidity

Marc Ruoß, Silas Rebholz, Marina Weimer, Carl Grom-Baumgarten, Kiriaki Athanasopulu, Ralf Kemkemer, Hanno Käß, Sabrina Ehnert, Andreas K. Nussler

Abstract

Drug-induced liver toxicity is one of the most common reasons for the failure of drugs in clinical trials and frequent withdrawal from the market. Reasons for such failures include the low predictive power of in vivo studies, that is mainly caused by metabolic differences between humans and animals, and intraspecific variances. In addition to factors such as age and genetic background, changes in drug metabolism can also be caused by disease-related changes in the liver. Such metabolic changes have also been observed in clinical settings, for example, in association with a change in liver stiffness, a major characteristic of an altered fibrotic liver. For mimicking these changes in an in vitro model, this study aimed to develop scaffolds that represent the rigidity of healthy and fibrotic liver tissue. We observed that liver cells plated on scaffolds representing the stiffness of healthy livers showed a higher metabolic activity compared to cells plated on stiffer scaffolds. Additionally, we detected a positive effect of a scaffold pre-coated with fetal calf serum (FCS)-containing media. This pre-incubation resulted in increased cell adherence during cell seeding onto the scaffolds. In summary, we developed a scaffold-based 3D model that mimics liver stiffness-dependent changes in drug metabolism that may more easily predict drug interaction in diseased livers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver physiology and pathology · 3D Printing in Biomedical Research · Pancreatic function and diabetes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany

Faculty of Applied Chemistry, Reutlingen University, 72762 Reutlingen, Germany

Faculty of Basic Science, University of Applied Sciences Esslingen, 73728 Esslingen am Neckar, Germany

Funding

Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tübingen

References (55)

Show source-provided references
1. Engineered liver platforms for different phases of drug development10.1016/j.tibtech.2016.08.001 ↗
2. Species differences between mouse, rat, dog, monkey and human cyp-mediated drug metabolism, inhibition and induction10.1517/17425255.2.6.875 ↗
3. In vitro models for liver toxicity testing10.1039/C2TX20051A ↗
4. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and adme10.1007/s00204-013-1078-5 ↗
5. Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating10.1124/dmd.105.007708 ↗
6. Ruoß, M., Vosough, M., Königsrainer, A., Nadalin, S., Wagner, S., Sajadian, S., Huber, D., Heydari, Z., Ehnert, S., and Hengstler, J.G. (2020). Towards improved hepatocyte cultures: Progress and limitations. Food Chem. Toxicol., 111188.10.1016/j.fct.2020.111188 ↗
7. Culture and functional characterization of human hepatoma HepG2 cells10.1007/978-1-4939-2074-7_5 ↗
8. Long-term culture of primary hepatocytes: New matrices and microfluidic devices10.1007/s12072-013-9487-3 ↗
9. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies
10. Epigenetic reprogramming of human hepatoma cells: A low-cost option for drug metabolism assessment10.1016/j.jcmgh.2017.11.006 ↗
11. Substrate stiffness regulates primary hepatocyte functions10.1039/C5RA15208A ↗
12. 3D cultivation techniques for primary human hepatocytes10.3390/microarrays4010064 ↗
13. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells10.1089/ten.tec.2014.0152 ↗
14. Hepatocyte-matrix interaction10.1007/BF02871913 ↗
15. Biomaterials for liver tissue engineering10.1007/s12072-013-9503-7 ↗
16. Ruoß, M., Häussling, V., Schügner, F., Olde Damink, L., Lee, S., Ge, L., Ehnert, S., and Nussler, A. (2018). A standardized collagen-based scaffold improves human hepatocyte shipment and allows metabolic studies over 10 days. Bioengineering, 5.10.3390/bioengineering5040086 ↗
17. Matrix elasticity directs stem cell lineage specification10.1016/j.cell.2006.06.044 ↗
18. Cozzolino, A.M., Noce, V., Battistelli, C., Marchetti, A., Grassi, G., Cicchini, C., Tripodi, M., and Amicone, L. (2016). Modulating the substrate stiffness to manipulate differentiation of resident liver stem cells and to improve the differentiation state of hepatocytes. Stem Cells Int., 2016.10.1155/2016/5481493 ↗
19. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha10.1002/hep.28450 ↗
20. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease10.1111/j.1530-0277.2012.01901.x ↗
21. Ecm proteins in a microporous scaffold influence hepatocyte morphology, function, and gene expression10.1038/srep37427 ↗
22. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins10.1007/s10565-011-9208-4 ↗
23. Ye, S., Boeter, J.W.B., Penning, L.C., Spee, B., and Schneeberger, K. (2019). Hydrogels for liver tissue engineering. Bioengineering, 6.10.3390/bioengineering6030059 ↗
24. Heydari, Z., Najimi, M., Mirzaei, H., Shpichka, A., Ruoss, M., Farzaneh, Z., Montazeri, L., Piryaei, A., Timashev, P., and Gramignoli, R. (2020). Tissue engineering in liver regenerative medicine: Insights into novel translational technologies. Cells, 9.10.3390/cells9020304 ↗
25. Mitry, R.R., and Hughes, R.D. (2012). Human hepatocytes: Isolation, culture, and quality procedures. Human Cell Culture Protocols, Humana Press.10.1007/978-1-61779-367-7 ↗
26. Greater scaffold permeability promotes growth of osteoblastic cells in a perfused bioreactor10.1002/term.1701 ↗
27. Development of polymer based cryogel matrix for transportation and storage of mammalian cells10.1038/srep41551 ↗
28. Three-layered scaffolds for artificial esophagus using poly (varepsilon-caprolactone) nanofibers and silk fibroin: An experimental study in a rat model10.1002/jbm.a.35347 ↗
29. An injectable hydrogel prepared using a peg/vitamin e copolymer facilitating aqueous-driven gelation10.1021/acs.biomac.6b01148 ↗
30. Ruoß, M., Kieber, V., Rebholz, S., Linnemann, C., Rinderknecht, H., Häussling, V., Häcker, M., Olde Damink, L.H., Ehnert, S., and Nussler, A.K. (2020). Cell-type-specific quantification of a scaffold-based 3D liver co-culture. Methods Protoc., 3.10.3390/mps3010001 ↗
31. Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism10.1007/s00204-011-0733-y ↗
32. Ruoß, M., Damm, G., Vosough, M., Ehret, L., Grom-Baumgarten, C., Petkov, M., Naddalin, S., Ladurner, R., Seehofer, D., and Nussler, A. (2019). Epigenetic modifications of the liver tumor cell line HepG2 increase their drug metabolic capacity. Int. J. Mol. Sci., 20.10.3390/ijms20020347 ↗
33. Decrease of global methylation improves significantly hepatic differentiation of ad-mscs: Possible future application for urea detoxification10.3727/096368912X638946 ↗
34. Neohepatocytes from alcoholics and controls express hepatocyte markers and display reduced fibrogenic TGF-β/smad3 signaling: Advantage for cell transplantation?10.1111/j.1530-0277.2009.01140.x ↗
35. Cytochrome p450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation10.1016/j.pharmthera.2012.12.007 ↗
36. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease10.1002/hep.23312 ↗
37. Non-invasive diagnosis of alcoholic liver disease10.3748/wjg.v20.i40.14626 ↗
38. Effects of liver disease on pharmacokinetics10.2165/00003088-199937050-00004 ↗
39. Animal models of chronic liver diseases10.1152/ajpgi.00199.2012 ↗
40. Substrate elasticity controls cell proliferation, surface marker expression and motile phenotype in amniotic fluid-derived stem cells10.1016/j.jmbbm.2012.10.001 ↗
41. Increasing mechanical strength of gelatin hydrogels by divalent metal ion removal10.1038/srep04706 ↗
42. Physicochemical properties of collagen, gelatin and collagen hydrolysate derived from bovine limed split wastes
43. Pure gelatin microcarriers: Synthesis and use in cell attachment and growth of fibroblast and endothelial cells10.1007/BF02623470 ↗
44. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease10.1002/hep4.1121 ↗
45. Liver fibrosis10.1172/JCI24282 ↗
46. Sacchi, M., Bansal, R., and Rouwkema, J. (2020). Bioengineered 3d models to recapitulate tissue fibrosis. Trends Biotechnol.10.1016/j.tibtech.2019.12.010 ↗
47. Impact of pre-incubation time of silk fibroin scaffolds in culture medium on cell proliferation and attachment10.1016/j.tice.2017.09.002 ↗
48. Combined effect of cryogel matrix and temperature-reversible soluble–insoluble polymer for the development of in vitro human liver tissue10.1021/acsami.5b08607 ↗
49. Glutathione and glutathione s-transferase levels in patients with liver metastases of colorectal cancer and other hepatic disorders10.5152/tjg.2016.15457 ↗
50. Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance10.3748/wjg.v22.i1.72 ↗
51. Phase ii drug metabolizing enzymes10.5507/bp.2010.017 ↗
52. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling10.1208/s12248-016-0019-7 ↗
53. Cell sources for in vitro human liver cell culture models10.1177/1535370216657448 ↗
54. Discovering cell-adhesion peptides in tissue engineering: Beyond rgd10.1016/j.tibtech.2018.01.008 ↗
55. Liver inflammation and fibrosis10.1172/JCI88881 ↗